Navigation Links
Ikaria® to Present at 2011 Lazard Capital Markets Healthcare Conference
Date:11/8/2011

HAMPTON, N.J., Nov. 8, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2011 Lazard Capital Markets 8th Annual Healthcare Conference.  Mr. Tasse's presentation will be given on Tuesday, November 15, 2011 at 3:00 p.m. EST at The Pierre Hotel in New York, NY.

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings.  Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The Company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The Company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.comCompany Contact:Media Contacts:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372

(212) 827-0020samina.bari@ikaria.com

csojda@tiberend.com
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria® Names New Chief Financial Officer
2. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
3. Ikaria® Launches Next-Generation Drug-Delivery System
4. Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
5. Ikaria® CEO Daniel Tasse Elected to PhRMA Board of Directors
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership College ... a thousand acres of soybeans, corn and wheat, and raises peas, sweet corn, baby ... for the fresh market. He also operates a roadside stand and raises broilers for ...
(Date:1/18/2017)... FORT LAUDERDALE, FL (PRWEB) , ... January 18, ... ... and how to manage it from the number one doctor-recommended OTC antiperspirant, Certain ... population and often go untreated. , Certain Dri created this infographic to explain ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
Breaking Medicine News(10 mins):